Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates
暂无分享,去创建一个
A. Kwa | S. J. Chung | T. Tan | K. Ko | R. Ong | J. Teo | Hong Yi Chang | C. Tang | S. H. Tan
[1] A. Kwa,et al. Genomic Surveillance of Carbapenem-Resistant Klebsiella pneumoniae from a Major Public Health Hospital in Singapore , 2022, Microbiology spectrum.
[2] P. Tamma,et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] OUP accepted manuscript , 2022, Clinical Infectious Diseases.
[4] T. Alioto,et al. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by WGS. , 2021, International journal of antimicrobial agents.
[5] M. Castanheira,et al. Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals. , 2021, International journal of antimicrobial agents.
[6] A. Kwa,et al. Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa , 2021, mSphere.
[7] G. Hansen. Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria , 2021, Infectious Diseases and Therapy.
[8] A. Kwa,et al. Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in Singapore , 2021, Emerging microbes & infections.
[9] Stephen C. Watts,et al. Genomic surveillance framework and global population structure for Klebsiella pneumoniae , 2020, bioRxiv.
[10] Apoorv Kalra,et al. A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline , 2020, Infectious Diseases and Therapy.
[11] R. Bonomo,et al. Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress". , 2020, Infectious disease clinics of North America.
[12] O. Lomovskaya,et al. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam , 2020, Antimicrobial Agents and Chemotherapy.
[13] S. Kuo,et al. Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016. , 2020, International journal of antimicrobial agents.
[14] Jason C. Gallagher,et al. Eravacycline: The Tetracyclines Strike Back , 2019, The Annals of pharmacotherapy.
[15] M. Souli,et al. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance , 2019, BMC Infectious Diseases.
[16] H. Derendorf,et al. Nonlinear Protein Binding: Not What You Think. , 2018, Journal of pharmaceutical sciences.
[17] P. Nordmann,et al. High Rate of Association of 16S rRNA Methylases and Carbapenemases in Enterobacteriaceae Recovered from Hospitalized Children in Angola , 2018, Antimicrobial Agents and Chemotherapy.
[18] D. C. Griffith,et al. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae , 2017, Antimicrobial Agents and Chemotherapy.
[19] Oon Tek Ng,et al. Clinical and Molecular Epidemiology of Carbapenem-Resistant Enterobacteriaceae Among Adult Inpatients in Singapore. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] H. Derendorf,et al. A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding. , 2017, International journal of antimicrobial agents.
[21] A. Kwa,et al. Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot , 2016, Microorganisms.
[22] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .
[23] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .